Solid Tumor Clinical Trials in Palo Alto, California

7 studies are recruiting for solid tumor in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   Lucile Packard Children's Hospital at Stanford, Palo Alto, California

   Locations

   9 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

2. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

   The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

   Stage

   Phase 2

   Ages

   1 and older

   Site

   Stanford Medicine Children's Health (Data Collection Only), Palo Alto, California

   Locations

   16 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05985161 on ClinicalTrials.gov

3. Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

   This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn …

   Stage

   Not phased

   Ages

   Any age

   Site

   Lucile Packard Children's Hospital Stanford University, Palo Alto, California

   Locations

   164 in total

   Run by

   Children's Oncology Group

   See if you can join NCT00736749 on ClinicalTrials.gov

4. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Cancer Institute, Stanford University, Palo Alto, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

5. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #123, Palo Alto, California

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

6. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

   This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site-111, Palo Alto, California

   Locations

   17 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06384807 on ClinicalTrials.gov

7. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

   The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-sma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Women's Cancer Center, Palo Alto, California

   Locations

   58 in total

   Run by

   Eisai Inc.

   See if you can join NCT04300556 on ClinicalTrials.gov